Americana Partners LLC Buys 1,381 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Americana Partners LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,295 shares of the pharmaceutical company’s stock after acquiring an additional 1,381 shares during the period. Americana Partners LLC’s holdings in Vertex Pharmaceuticals were worth $21,067,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of VRTX. MADDEN SECURITIES Corp purchased a new position in Vertex Pharmaceuticals during the 3rd quarter worth $26,000. Meeder Asset Management Inc. acquired a new stake in Vertex Pharmaceuticals in the second quarter worth about $26,000. Community Financial Services Group LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter worth about $26,000. Elevation Wealth Partners LLC boosted its holdings in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 28 shares in the last quarter. Finally, Pingora Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth about $32,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $558.88 on Friday. The firm has a market cap of $141.85 billion, a PE ratio of 32.53, a PEG ratio of 2.59 and a beta of 0.28. The firm has a fifty day moving average of $523.21 and a 200 day moving average of $479.47. Vertex Pharmaceuticals Incorporated has a one year low of $403.16 and a one year high of $563.80.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The company had revenue of $3.33 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the business earned $4.52 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 16.74 EPS for the current fiscal year.

Analyst Ratings Changes

VRTX has been the subject of several research reports. Morgan Stanley assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 1st. They set an “overweight” rating and a $665.00 price objective for the company. Jefferies Financial Group lifted their price objective on Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, September 23rd. Cantor Fitzgerald raised their target price on Vertex Pharmaceuticals from $590.00 to $595.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Evercore lifted their price target on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research report on Wednesday, September 2nd. Finally, Truist Financial boosted their price target on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $579.81.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.